Breakthrough trial aims to customize breast cancer treatment while cutting chemo side effects
NCT ID NCT07239271
Summary
This large study aims to improve treatment for HER2-positive breast cancer by personalizing therapy based on each patient's response. Researchers will test whether adjusting treatment intensity—increasing it for some patients while decreasing it for others—can lead to better outcomes with fewer side effects. The trial will involve 2,000 women with early-stage breast cancer who haven't started treatment yet.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH HER2-POSITIVE BREAST CANCER (BC) SUITABLE FOR NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.